Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin lead-in before pegylated interferon + ribavirin for recurrent HCV after liver transplantation
2010-018870-19Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ribavirin and pegylated interferon alpha in hepatitis C virus infection (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Sustained virological response. Started Sep 2010; status: active.
02
Drugs
ribavirinpegylated interferon alpha
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-018870-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018870-19.